Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARTLNASDAQ:BNTCNASDAQ:PHIONASDAQ:TCDA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARTLArtelo Biosciences$1.01+0.5%$0.97$0.82▼$1.59$3.30M1.03133,675 shs5,096 shsBNTCBenitec Biopharma$12.87-2.1%$13.63$5.74▼$16.90$301.70M0.3440,963 shs3,357 shsPHIOPhio Pharmaceuticals$2.06+14.0%$1.67$0.97▼$9.79$9.86M0.992.37 million shs1.05 million shsTCDATricida$0.13$0.09▼$13.85$6.01M0.2217.62 million shs31.13 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARTLArtelo Biosciences-1.96%-4.76%+17.79%-28.32%-25.37%BNTCBenitec Biopharma-4.44%-8.94%+4.04%+26.35%+42.05%PHIOPhio Pharmaceuticals+2.26%-3.72%+4.02%+1.69%-71.45%TCDATricida0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARTLArtelo Biosciences2.5623 of 5 stars3.82.00.00.03.30.01.3BNTCBenitec Biopharma2.6403 of 5 stars3.63.00.00.03.02.50.0PHIOPhio Pharmaceuticals3.0768 of 5 stars3.54.00.00.03.00.81.3TCDATricidaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARTLArtelo Biosciences 3.50Strong Buy$5.50447.26% UpsideBNTCBenitec Biopharma 3.22Buy$24.7192.10% UpsidePHIOPhio Pharmaceuticals 3.00Buy$4.0093.89% UpsideTCDATricida 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest TCDA, ARTL, PHIO, and BNTC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/28/2025ARTLArtelo BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.004/10/2025BNTCBenitec BiopharmaJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$18.00 ➝ $20.004/8/2025PHIOPhio PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.004/2/2025ARTLArtelo BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.003/24/2025BNTCBenitec BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.003/4/2025ARTLArtelo BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.002/27/2025ARTLArtelo BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.002/21/2025BNTCBenitec BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.002/19/2025PHIOPhio PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.00(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARTLArtelo BiosciencesN/AN/AN/AN/A$4.12 per shareN/ABNTCBenitec Biopharma$80K3,771.21N/AN/A$3.24 per share3.97PHIOPhio PharmaceuticalsN/AN/AN/AN/A$18.57 per shareN/ATCDATricidaN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARTLArtelo Biosciences-$9.29M-$3.05N/AN/AN/AN/A-104.59%-94.06%N/ABNTCBenitec Biopharma-$21.75M-$1.51N/AN/AN/AN/A-44.61%-41.25%N/APHIOPhio Pharmaceuticals-$10.83M-$10.92N/A0.55N/AN/A-134.57%-108.39%N/ATCDATricida-$176.57M-$2.36N/AN/AN/AN/AN/A-103.81%N/ALatest TCDA, ARTL, PHIO, and BNTC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025ARTLArtelo Biosciences-$0.13-$0.72-$0.59-$0.72N/AN/A3/3/2025Q4 2024ARTLArtelo Biosciences-$0.74-$1.17-$0.43-$1.17N/AN/A2/14/2025Q2 2025BNTCBenitec Biopharma-$0.55-$0.36+$0.19-$0.33N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARTLArtelo BiosciencesN/AN/AN/AN/AN/ABNTCBenitec BiopharmaN/AN/AN/AN/AN/APHIOPhio PharmaceuticalsN/AN/AN/AN/AN/ATCDATricidaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARTLArtelo BiosciencesN/A7.157.15BNTCBenitec BiopharmaN/A25.4815.01PHIOPhio PharmaceuticalsN/A6.386.38TCDATricidaN/A4.874.87Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARTLArtelo Biosciences0.87%BNTCBenitec Biopharma52.19%PHIOPhio Pharmaceuticals57.31%TCDATricidaN/AInsider OwnershipCompanyInsider OwnershipARTLArtelo Biosciences0.83%BNTCBenitec Biopharma1.30%PHIOPhio Pharmaceuticals0.59%TCDATricida35.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARTLArtelo Biosciences53.28 million3.20 millionNot OptionableBNTCBenitec Biopharma2023.45 million23.15 millionNo DataPHIOPhio Pharmaceuticals104.78 million6.85 millionNot OptionableTCDATricida5755.67 million35.85 millionNot OptionableTCDA, ARTL, PHIO, and BNTC HeadlinesRecent News About These CompaniesTricida CEO to Pay $14 Million in Class Suit Over Drug ProgressMarch 4, 2025 | news.bloomberglaw.comPatrick G Enright's Net WorthMay 5, 2024 | benzinga.comSierraConstellation Partners Receives Industry Recognition for Work with TricidaFebruary 6, 2024 | finance.yahoo.comTricida Inc (TCDAQ)January 13, 2024 | es.investing.comEmerging Therapies in the Treatment of Clostridium difficile-Associated DiseaseMay 30, 2023 | medscape.comVaniam Group Hires Paula Franson to Lead Clinical Strategy & Solutions - Yahoo FinanceApril 18, 2023 | news.google.comMetabolic Acidosis Market to Witness Growth by 2032, Estimates ... - Digital JournalApril 17, 2023 | news.google.comReal-time PCR as a Diagnostic Tool for Bacterial DiseasesApril 12, 2023 | medscape.comChronic Kidney Disease Drugs Market Expected To Propel Market ... - Digital JournalApril 10, 2023 | news.google.comChronic Kidney Disease Drugs Market Huge Growth in Future ... - Digital JournalApril 6, 2023 | news.google.comTricida Heading For Ch. 11 Confirmation Fight With Creditors - Law360March 24, 2023 | news.google.comAlicia Dixon Joins COPILOT Provider Support Services as VP of Strategy Development & Execution - Yahoo FinanceMarch 14, 2023 | news.google.comAlicia Dixon Joins COPILOT Provider Support Services as VP of ... - Yahoo FinanceMarch 14, 2023 | news.google.comTricida Heads To Ch. 11 Mediation Over Creditor Plan Issues - Law360March 6, 2023 | news.google.comTroubled Adamis To Merge With Private DMK, Focus On ... - ScripMarch 1, 2023 | news.google.comRelease Opt Out Trips Up Tricida Ch. 11 Disclosure Approval - Law360February 27, 2023 | news.google.comRenibus Buys Tricida's Kidney Drug Veverimer In Ch. 11 Sale - Law360February 21, 2023 | news.google.comSTONEHILL CAPITAL MANAGEMENT LLC Buys 2, Sells 3 in 4th ... - GuruFocus.comFebruary 18, 2023 | news.google.comTop 5 4th Quarter Trades of ORBIMED ADVISORS LLC - GuruFocus.comFebruary 18, 2023 | news.google.comTricida, Inc. (TCDA) Stock Historical Prices & Data - Yahoo FinanceFebruary 14, 2023 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTCDA, ARTL, PHIO, and BNTC Company DescriptionsArtelo Biosciences NASDAQ:ARTL$1.00 +0.01 (+0.50%) As of 10:48 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.Benitec Biopharma NASDAQ:BNTC$12.86 -0.28 (-2.09%) As of 10:49 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.Phio Pharmaceuticals NASDAQ:PHIO$2.06 +0.25 (+13.98%) As of 10:50 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.Tricida NASDAQ:TCDATricida, Inc. is a pharmaceutical company. It focuses on the development and commercialization of its product, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease. The company was founded by Gerrit Klaerner and Craig Jon Hawker on May 22, 2013 and is headquartered in South San Francisco, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Huge S&P 500 Winners From Trump Trade Deal & The Biggest Loser Why SoundHound’s Growth and Zero Debt Are a Bullish Signal Palantir’s Latest Deal Could Put a Freeze on Its Stock Price Lyft: Profitability Milestone and Buyback Fuel Investor Optimism A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready Why DraftKings Share Price Could Soar to Multi-Year Highs 3 Stocks Plan +$130B in Buybacks: Why Markets Wanted Even More BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
